|
|
Article: Rosetta Inpharmatics Researchers Publish Landmark Study Highlighting the Future of the Human Genome; Pioneering Gene Validation Study in Human Genome Issue of "Nature".
- Article from:
- Business Wire
- Article date:
- February 11, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors & Medical Writers
KIRKLAND, Wash.--(BUSINESS WIRE)--Feb. 11, 2001
Rosetta Inpharmatics (NASDAQ:RSTA) today announced the publication of a landmark paper demonstrating Rosetta Genecipher(TM) Genome Annotation Technology, which identifies and validates all the genes in the human genome, discovers previously unknown genes, and helps understand their function. Current attempts to identify genes in the sequence information generated by the Human Genome Project rely on computers, which are only capable of making guesses based on already known information. Rosetta Genecipher technology uses a new and unanticipated application of biological ...